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ORIGINAL ARTICLE
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in
51 adult and pediatric patients
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M. E. Abatea, A. Paiolia, Z. Szucsb, L. D’ambrosiod , K. Scotlandia, F. Fagiolie, S. Asafteie and S. Ferraria
aIstituto Ortopedico Rizzoli, Bologna, Italy; bRoyal Marsden Hospital and Institute of Cancer Research, London, UK; cIstituto Nazionale Tumori,
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ABSTRACT
Background: Data on temozolomide (TEM) and irinotecan (IRI) activity in recurrent Ewing sarcoma
(EWS), especially in adult patients, are limited.
Methods: Patients receiving TEM 100mg/m2/day oral, and IRI 40mg/m2/day intravenous, days 1–5,
every 21 days, were included in this multi-institutional retrospective study. Disease control rate (DCR)
[overall response rate (ORR) [complete response (CR)þpartial response (PR)]þ stable disease (SD)],
6-months progression-free survival (6-mos PFS) and 1-year overall survival (OS) were assessed.
Results: The median age of the 51 patients was 21 years (range 3–65 years): 34 patients (66%) were
adults (18 years of age), 24 (48%) had ECOG 1 and 35 (69%) were presented with multiple site recur-
rence. TEMIRI was used at first relapse/progression in 13 (25%) patients, while the remainder received
TEMIRI for second or greater relapse/progression. Fourteen (27%) patients had received prior myeloa-
blative therapy with busulfan and melphalan. We observed five (10%) CR, 12 (24%) PR and 19 (37%)
SD, with a DCR of 71%. 6-mos PFS was 49% (95% CI 35–63) and it was significantly influenced by
ECOG (6-mos PFS 64% [95% CI 45–83] for ECOG 0, 34% [95% CI 14–54] for ECOG 1; p¼ .006) and
LDH (6-mos PFS 62% [95% CI 44–79] for normal LDH, 22% [95% CI 3–42] for high LDH; p¼ .02), with
no difference according to line of treatment, age and metastatic pattern. One-year OS was 55% (95%
CI 39–70), with RECIST response (p¼ .001) and ECOG (p¼ .0002) independently associated with out-
come. Grade 3 and 4 toxicity included neutropenia in 12% of patients, thrombocytopenia in 4%, diar-
rhea in 4%.
Conclusions: This series confirms the activity of TEMIRI in both adults and pediatric patients. This
schedule offers a 71% DCR, independently of the line of chemotherapy. Predictive factors of response
are ECOG and LDH.
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Introduction
Ewing sarcoma (EWS) is a malignant, small round cell tumor of
bone and soft tissue with varying degrees of neuroectodermal
differentiation, and pathognomonic translocations [1]. Since
the introduction of multi-agent chemotherapy schedules,
approximately 70% of patients with localized disease are cured
with a combination of systemic and local therapies [2–4].
However, the outcome of patients with recurrent EWS
remains poor with 5-year overall survival (OS) ranging from
8% to 15% in different series [5–9] Various chemotherapy
regimens have been evaluated in this setting including high-
dose chemotherapy with stem cells rescue [10], alkylating
agents [11,12], camptothecin derivatives [13,14] and platinum
agents [15]. Only few salvage schedules have emerged for
‘routine’ use, including cyclophosphamide and topotecan
[16,17] as well as temozolomide and irinotecan (TEMIRI),
gemcitabine and docetaxel (GEM-TXT) [18,19], and high-dose
ifosfamide (HDIFO) [20,21]. Most of the available data
regarding the activity and toxicity of TEMIRI are from
retrospective studies on pediatric EWS populations
(Table 1) [13,22–30].
Therefore, the aim of this study was to study the efficacy
and safety profile of the TEMIRI schedule, and to identify fac-
tors predictive of response for pediatric and adult EWS
patients treated with this combination in different European
referral centers.
Material and methods
A joint retrospective analysis between the Italian Sarcoma
Group and the Royal Marsden Hospital was planned, in order
to collect data on patients with recurrent EWS treated
with TEMIRI.
The study was approved by the institutional review board
of all five participating centers: four Italian referral centers
(Rizzoli Institute, Bologna; Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan; IRCCS Candiolo, Torino; OIRM, Torino)
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and the Royal Marsden Hospital/Institute of Cancer Research,
London, UK.
All patients/legal tutors included in the study signed
informed consent for treatment and privacy according to the
requirements of each individual institution.
The analysis period was set from March 2010 to
April 2016.
Patients with the following characteristics were included:
(1) diagnosis of EWS, (2) recurrent disease or disease pro-
gressing on frontline treatment, not amenable to surgical
excision, (3) treatment with TEMIRI, (4) availability of demo-
graphic, clinical and follow-up data, (5) measurable disease
as per RECIST 1.1 (complete response [CR], partial response
[PR], stable disease [SD] or progressive disease [PD]) and
(6) available radiological images for review.
The diagnosis was confirmed in all cases by an experi-
enced sarcoma pathologist. Drugs were administered as
follows: temozolomide 100mg/m2/day oral, days 1–5 and
irinotecan 40mg/m2/day intravenous, days 1–5, every
21 days. Gastrointestinal toxicity prophylaxis with oral cef-
ixime 400mg/day, days 1–10, was recommended in all
patients.
Patient characteristics including age, gender, ECOG per-
formance status, LDH, primary tumor site, pattern of meta-
stases, number of prior line of treatments, response to
therapy, toxicity, date of progression, date of last follow-up
or death were obtained from the databases or the patient
clinical chart and collected in a study-specific case
report form.
Response was assessed using the Response Evaluation
Criteria In Solid Tumors (RECIST) version 1.1 [31]. Patients
were assessed for response after the first two cycles and, in
case of response or stable disease, every two or three follow-
ing courses of therapy. Response was assessed according to
RECIST 1.1. Objective response was given by complete
response [CR]þpartial response [PR] and overall response
rate (ORR) was calculated as the proportion of patients
achieving either CR or PR. Disease control rate (DCR) was the
duration of CR, PR and SD.
Patients undergoing surgery or radiotherapy with curative
intent and achieving a complete remission of all sites of dis-
ease were classified as patients in disease-free status (DFS).
Toxicity data were collected from clinical chart and from
‘patient-toxicity’ questionnaires, in some of the centers.
Toxicity was graded according to the Common Toxicity
Criteria for Adverse Events (CTCAE) version 4. In case of
grade 4, neutropenia prophylactic use of G-CSF was allowed;
therapeutic use of G-CSF was mandatory in case of febrile
neutropenia.
Treatment was discontinued at progression or unaccept-
able toxicity. All patients who received at least one cycle
were included in an intention-to-treat analysis.
Progression-free survival (PFS) and overall survival (OS)
were estimated according to the Kaplan and Meier method
with their respective 95% confidence intervals (CI) and calcu-
lated from the first day of TEMIRI administration to tumor
progression or death or last follow-up visit, respectively.
Results
Fifty-one patients were identified. The median age was 21
years (range: 3–65 years). Seventeen patients (34%) were
18 years, and 34 (66%) were in the adult age range (i.e.,
>18 years of age). Seventeen patients (33%) were female
and 34 (77%) were male. Twenty-six (52%) patients had an
ECOG 0, 20 patients (40%) ECOG 1 and four patients (8%)
had an ECOG 2. The clinical characteristics are displayed in
Table 2.
Thirty-five patients (69%) had multiple sites of metastatic
disease (with additional bone marrow involvement in 2), 11
patients (22%) had lung only disease and five (9%) had bone
and local recurrence.
All patients were pretreated: 13 patients (25%), relapsing
after adjuvant chemotherapy, received TEMIRI as first line
therapy for recurrent/primary refractory disease, and 38
patients (75%) received this schedule as 2nd line therapy
(25 patients as 2nd line, nine as 3rd line, four as 4th line of
treatment). Fourteen (27%) patients had previously been
treated with busulfan and melphalan (BuMel) with peripheral
blood stem cell rescue (PBSC).
The median number of cycles was 5 (range: 1–31 cycles),
with one patient with bone, lung, adrenal and soft tissue
involvement, receiving up to 31 cycles as fourth line chemo-
therapy, achieving a 24 months SD and eventually under-
going CNS progression.
Table 1. Response rate (RR) to different temozolomide and irinotecan combination in Ewing sarcoma.
Phase No. pts
Median age,
years (range) CR/PR RR
TMZ
(mg/m2)
irinotecan
(mg/m2) daysweek
Other
agents
Wagner et al. (PBC 2007) [13] R 16 18 (7–33) 1/3 29% 100 5 IV 10–20 5 2 None
Casey et al. (PBC 2009) [22] R 19 19.5 (2–40) 5/7 63% 100 5 IV 20 5 2 None
Hernandez-Marques et al. (An Ped 2013) [23] R 8 13 (6–18) 0/3 37% 80–100 5 IV 10–20 5 2 None
Raciborska et al. (PBC 2013) [24] R 22 14.3 5/7 54% 125 5 IV 50 5 VCR
McKnall-Knapp et al. (PBC 2010) [25] I 1 Na 0/1 100% 100 5 IV 20 5 2 VCR
Wagner et al. (PBC 2010) [26] I 5 Uk (<21) 1/1 40% 100–150 5 PO 35–90 5 VCR
PO 35–90 5 2
Wagner et al. (PBC 2013) [27] I 2 20,22 1/1 100% 150 5 PO 90 5 VCR
BEV
Bagatell et al. (PBC 2014) [28] I 7 Uk (<21) 0/1 14% 100–150 5 PO 50–90 5 TMS
Kurucu et al. (Ped Hem Onc 2015) [29] R 20 14 (1–18) uk 55% 100 5 IV 20 5 2 None
Anderson et al. (Exp Opin Investig Drugs 2008) [30] R 25 15 (uk) 7/9 64% 100 5 IV 10 5 2 None
R: retrospective; I: Phase I; IV: intravenous; PO: per os; TMZ: temozolomide; VCR: vincristine; BEV: bevacizumab; TMS: temsirolimus; uk: unknown; na: not applic-
able; PBC: Pediatric Blood and Cancer: An Ped: Annals of Pediatrics; Ped Hem Onc: Pediatric Hematology and Oncology.
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The response rate was 34% (CR 5 [10%], PR 12 [24%]) with
LDH (p¼ .004) and ECOG (p¼ .004) predicting for response
(Figure 1, Table 3). There was no significant difference in ORR
according to age (Table 3).
Ten patients became disease-free (DFS cohort): five
patients achieved CR with TEMIRI only (in two of them radi-
ation therapy was added); five patients, in SD or PR with
TEMIRI, DFS was achieved adding surgery (in three), radiation
therapy (in one) or both (one).
The 6-months PFS was 49% (95% CI 35–63) and
the median PFS was 3.9 months (range: 1–29 months)
(Figure 2).
There was a significant difference in 6-month PFS accord-
ing to ECOG (ECOG 0 6-months PFS 64% vs. ECOG 1
6-months PFS 40% vs. ECOG 2 6-months PFS 0 p¼ .0002)
and LDH (LDH normal 6-months PFS 62% vs. LDH high
6-months PFS 22%, p¼ .02), whereas no significant differen-
ces were found according to age, sex, metastatic pattern,
prior use of BuMel or line of treatment (Table 4).
One-year overall survival rate was 55% (95% CI 39–70).
One-year OS was significantly better for responders: 84% for
patients achieving an objective response (CR/PR), 64% for
those with SD and 9% for those with PD, p¼ .0001 (Figure 2,
Table 5).
Other factors associated with increased survival were
ECOG 0 (ECOG 0 1-year OS 81% vs. ECOG1 1-year OS 26%,
p¼ .001), normal LDH level at TEMIRI treatment start (LDH
normal 1-year OS 67% vs. LDH high 1-year OS 28%, p¼ .04),
and patients achieving DFS after TEMIRI (DFS yes 1-year OS
100% vs DFS no 1-year OS 45%, p=.02) (Table 5).
After multivariate analysis, ECOG 0 (p¼ .0002) and LDH
(p¼ .01) were confirmed as factors independently associate
with OS (Table 6).
TEMIRI re-challenge
Two patients underwent TEMIRI re-challenge. One patient,
with a metastatic spine sarcoma, achieved a CR after four
Figure 1. Massive pleural effusion and lung metastases before (a) and (b) after two cycles of chemotherapy with temozolomide and irinotecan; lung apical nodule
before (c) and after (d) treatment; bilateral lung metastases and lower lung lobe pleura effusion before (e) and (f) after chemotherapy.
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cycles and TEMIRI was withdrawn after 10 cycles. Due to dis-
ease progression at 5 months off-therapy, he underwent
TEMIRI re-challenge achieving a PR (ongoing after 15 cycles
at last follow up). The second patient, also with lung meta-
stases, achieved a CR after six cycles on TEMIRI, and under-
went total lung irradiation. After 6 months he had a PD and
was re-challenged with TEMIRI, achieving a PR lasting
22 cycles.
Toxicity
The median number of TEMIRI cycles was 5 (range 1–31
cycles). Grade 3 and 4 toxicity included neutropenia in six
patients (12%), thrombocytopenia in two (4%) and diarrhea
in two (4%) patients (Table 7), with none of patients with
a> 10% weight loss. Nine patients (18%) had delayed treat-
ment, while in one patient dose reduction by 33% of the
scheduled doses was necessary due to combined grade 3–4
thrombocytopenia and neutropenia after the first cycle.
Growth factors were needed in four patients, two patients
required hospitalization (one for diarrhea and fever, one for
G4 thrombocytopenia requiring transfusions). Overall grade 3
and 4 was reported in 10/51 (20%) adult patients and in 7/10
(70%) pediatric cases, with median age for patients with tox-
icity (17 years, range 3–65), inferior to that of patients with
no toxicity (25 years, range 3–50).
Discussion
Treatment options for recurrent EWS and for disease pro-
gressing during frontline therapy include various chemother-
apy schedules [13,16,18–21], but the optimal sequence of
drugs remains to be defined. Prognostic factors at first recur-
rence associated with higher post-relapse survival are: the
interval from initial diagnosis to recurrence (better if more
than 2 years), disease sites at recurrence (worse if combined
bone and lung), serum LDH (worse if high) and the treatment
outcome [5–9]. Predictive factors for response to chemother-
apy are still to be identified. TEMIRI has been studied in
retrospective studies mainly including pediatric patients
[13,22–30] however, none of these studies have reported on
putative predictive markers of response and PFS. Only one
study has been published with single agent temozolomide
[11] while different schedules of single agent irinotecan are
reported in different trials [14,32,33]. Protracted irinotecan
infusion was shown to increase number of cells in S-phase
exposed to the drug [34]. The addition of temozolomide,
through DNA methylation, seems to cause localization and
enhancement of topoisomerase I cleavage complex allowing
irinotecan to more effectively stabilize the DNA–enzyme
complex [35]. Preclinical studies suggest that antitumor activ-
ity of the combination of temozolomide and irinotecan is
only partially dependent of O6-methylguanine-DNA methyl-
transferase and mismatch repair phenotypes in xenograft
models [36]. The two drugs hold different toxicities profiles
and different mechanism of resistance. In addition, the intro-
duction of third generation cephalosporin has resulted in a
reduction of the incidence of diarrhea, the major dose limit-
ing toxicity of the regimen [37].
The major limitation of the present series is its retrospect-
ive design, which might affect the uniformity of toxicity and
response assessment.
Nonetheless, our multicenter study is the largest study on
the combination of irinotecan and temozolomide in recurrent
and primary refractory EWS, and confirms that this combin-
ation is active in both adult and pediatric patients. Among
51 treated patients five achieved a complete response and
12 partial responses. It is important to note the relation
Table 2. Clinical characteristics of 51 patients with metastatic
Ewing sarcoma (EWS).
n (%)
Sex
Female 17 (33)
Male 34 (77)
ECOGa
0 26 (52)
1 24 (48)
Age
14 years 8 (16)
15–17 years 9 (18)
18 years 34 (66)
LDHb
High 19 (39%)
Normal 30 (61%)
Metastatic pattern
Multiple sitesc 35 (69%)
Lung 11 (22%)
Bone or LR 5 (9%)
Chemo lines at TEMIRI
1d 13 (25%)
2 38 (75%)
Previous HCT (BuMel)
Yes 14 (27%)
No 37 (73%)
LR: local recurrence; HCT (BuMel): high dose chemotherapy
with busulphan and melphalan.
aNot available in one patient.
bNon-available in two patients.
cIncluding bone marrow involvement in two patients.
d1st line in ES patients progressing/relapsing after adjuvant
standard chemotherapy.
Table 3. Analysis of response rate (RR) by clinical variable (total¼ 51).
CRþ PR (%) SD (%) PD (%)
Age
<18 years 3 (18) 10 (59) 4 (23) .1
18 years 14 (41) 9 (27) 11 (32)
Sex
Male 11 (32) 15 (44) 8 (24) .3
Female 6 (35) 4 (24) 7 (41)
Pre BuMel
Yes 4 (29) 7 (50) 3 (21) .5
No 13 (36) 12 (32) 12 (32)
Pattern of metastases at study entry
Multiple sites 9 (26) 12 (34) 14 (40) .1
Lung 5 (45) 5 (45) 1 (10)
LR or bone 3 (60) 2 (40) 0
LDH
High 4 (21) 4 (21) 11 (58) .004
Normal 11 (37) 15 (50) 4 (13)
Lines at TEMIRI
1 5 (39) 4 (31) 4 (31) .8
2 12 (32) 15 (39) 11 (29)
ECOG
0 8 (31) 15 (58) 3 (11) .004
1–2 9 (37) 4 (17) 11 (46)
CR: complete response; PR: partial response; SD: stable disease; PD: progressive
disease.
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observed between ORR and PFS in our population. In adult
patients, the ORR was higher compared to that of younger
patients, but this did not translate in a superior probability of
PFS that was not significantly different between adults and
pediatric patients.
6-months PFS: 49% (95% CI 35-63)
1-year OS: 55% (95% CI 39-70) 
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Figure 2. Outcome of adult and pediatric Ewing sarcoma patients treated with TEMIRI: (a) 6-months progression-free survival (PFS); (b) 1-year overall survival (OS);
(c) 1-year OS according to LDH levels before TEMIRI treatment; (d) 1-year OS according to radiological response (RECIST 1.1).
Table 4. Univariate analysis for progression-free survival (PFS).
Pts no. % 6-months PFS 95% CI p
Overall 51 49 35–63
Age
<18 years 9 44 12–77 .9
18 years 42 55 34–66
Sex
Female 17 43 19–68 .9
Male 34 42 35–69
Metastatic pattern
Lung 11 81 57–100 .3
Boneþ Loc Rec 5 60 17–100
Multiple sites 35 38 21–54
ECOG
0 26 64 45–83 .006
1 24 34 14–54
Chemo Line at TEMIRI
1 13 46 19–73 .8
2 38 50 33–66
LDH
High 19 22 3–42 .02
Normal 30 62 44–79
Pts: patients.
Table 5. Univariate analysis for overall survival (OS).
Pts no. % 1-year OS 95% CI p
Overall 51 55 39–70
Age
<18 years 17 49 19–78 .7
18 years 34 57 39–75
Sex
Female 17 48 20–76 .2
Male 34 62 44–80
Metastatic pattern
Lung 11 100 .08
Boneþ Loc Rec 5 80 45–100
Multiple sites 35 38 20–56
ECOG
0 26 81 64–98 .0001
1 24 26 5–47
Chemo Line at TEMIRI
1 13 81 56–100 .3
2 38 49 32–66
LDH
High 19 28 5–51 .04
Normal 30 67 48–86
RECIST response
CR/PR 17 84 64–100 .0001
SD 19 64 40–97
PD 15 9 0–25
DFS
Yes 10 100 .02
No 41 45 28–62
CR: complete response; PR: partial response; SD: stable disease; PD: progressive
disease; DFS: disease free status; progressive disease.
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At the same time it is important to underline that pro-
longed disease stabilization was reported with an adult
patient that was on treatment for more than 30 cycles
of TEMIRI.
On univariate analysis, the only two factors predictive for
response to TEMIRI in terms of PFS were ECOG and LDH, but
not the number of chemotherapy lines. This suggests that
TEMIRI can potentially be safely used in patients who have
already received more than one line for recurrent/progressive
disease, maintaining the goal of achieving a new response if
the performance status is still good and LDH in the nor-
mal range.
The survival analysis confirmed the importance of ECOG
and LDH and also demonstrated an association with OS and
response: in particular similar outcome was demonstrated for
patients achieving PR/CR and for those with a disease stabil-
ization, while patients progressing on TEMIRI represent a sub-
group with a very poor outcome. This study suggested that,
whenever possible, surgery and radiotherapy to all sites of
metastases should be performed, with all patients attaining a
disease remission (DFS group) in this series are alive at
1 year. Also, TEMIRI re-challenge might represent a thera-
peutic option for those patients relapsing after TEMIRI inter-
ruption, in case of disease complete remission.
The schedule we used, with 40mg/m2/die Irinotecan for
5 days, is manageable comparing the ones at lower dose
[10–20mg/m2/die for 5 days] for 2 weeks in the first pediatric
studies [38]. We observed less gastrointestinal toxicity than
previously reported in other studies [13]. Since temozolomide
has no overlapping toxicity with irinotecan, the hemato-
logical toxicities are quite similar to those ones observed
with monotherapy [13].
In conclusion, our study confirms the efficacy and safety
of temozolomide and irinotecan in recurrent/refractory
Ewing’s sarcoma in both the pediatric and adult population
and provides a benchmark for further studies.
In addition, our data indicate that irinotecan and temozo-
lomide should be considered as a control arm for future
randomized trials in relapsed EWS. The results of the random-
ized trial rEECur, presently ongoing (http://www.euroewing.
eu/clinical-trials/reecur/reecur-update) [39] comparing TEMIRI
with three other regimens adopted in patients with recurrent
EWS, will define the best treatment sequence. The activity
and toxicity profile of TEMIRI suggest that this combination
might be added to conventional chemotherapy combinations
in the first-line therapy setting.
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